Correlation Engine 2.0
Clear Search sequence regions


filter terms:
  • antitumor (1)
  • ligands (1)
  • platinum (1)
  • prodrugs (6)
  • Sizes of these terms reflect their relevance to your search.

    Platinum(II)-based drugs are widely used for the treatment of solid tumors, especially in combination protocols. Severe side effects and occurrence of resistance are the major limitations to their clinical use. To overcome these drawbacks, a plethora of Pt(IV) derivatives, acting as anticancer prodrugs, have been designed, synthesized and preclinically (often only in vitro) tested. Here, we summarize the recent progress in the development and understanding of the chemical properties and biochemical features of these Pt(IV) prodrugs, especially those containing bioactive molecules as axial ligands, acting as multi-functional agents. Even though no such prodrugs have been yet approved for clinical use, many show encouraging pharmacological profiles. Thus, a better understanding of their features is a promising approach towards improving the available Pt-based anticancer agents.

    Citation

    Mauro Ravera, Elisabetta Gabano, Michael J McGlinchey, Domenico Osella. Pt(IV) antitumor prodrugs: dogmas, paradigms, and realities. Dalton transactions (Cambridge, England : 2003). 2022 Feb 08;51(6):2121-2134

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 35015025

    View Full Text